Despite recent advances in immunotherapy and extensive research efforts, R/M head and neck cancer is still a clinical challenge. Since no curative treatment options are available in this setting, prolonging OS and symptom control is the ultimate treatment goal. In this retrospective analysis, we show that a modified TPEx regimen administered biweekly is a feasible, safe and effective regimen in unselected patients suffering from R/M SCCHN.
In the first-line platinum-sensitive setting, a combination chemotherapy according to the EXTREME regimen is regarded as the standard of care worldwide, although considerable shortcomings are linked to this protocol such as the high amount of patients (82%) suffering from severe grade 3/4 adverse events or the continuous administration of 5-FU for four days [
6]. Two recently published phase II studies demonstrated that substitution of 5-FU by a taxane might be equi-effective with respect to OS but yield in higher ORR and better toxicity profile [
12,
13]. The first study enrolled 54 patients and reported that conventional TPEx consisting of cisplatin/docetaxel given every 3 weeks plus cetuximab administered weekly results in an OS of 14 months (95% CI 11.3–17.3) and an ORR of 44% [
12]. However, two infectious events leading to death were observed [
12]. The second study compared three weekly cisplatin plus weekly cetuximab with or without paclitaxel resulting in a median OS of 11 month, a median PFS of 7 months and an ORR of 51.7% in the cisplatin/paclitaxel plus cetuximab group [
13]. Given the limitations of inter-trial comparisons, the low patient number and the retrospective nature of our analysis these results are completely in line with our findings. Patients receiving off-protocol modified biweekly TPEx had a median OS of 10.8 months (95% CI 6.7–14.2) and a median PFS of 6.3 months (95% CI 5.7–6.8) indicating a comparable efficacy of the biweekly TPEx regimen. Tumor shrinkage is a crucial issue for head and neck cancer patients leading to symptom relief and quality of life improvement, although response rates do not always translate into a prolonged OS as shown in the aforementioned trial. While the ORR of biweekly TPEx was 50% in our analysis, conventional TPEx was reported to yield in an ORR of 44.4%. ORR with cisplatin in combination with paclitaxel and cetuximab was numerically higher (51.7%), whereas the standard of care EXTREME regimen achieved tumor response in 36% of the patients [
6]. Of note, we observed four complete responders, whereas in the conventional TPEx regimen, no CRs were reported [
12]. This finding further supports the activity of modified TPEx given every other week. Interestingly, the DCR of 53.5%, we observed in our analysis was inferior compared to the other two cisplatin/taxane/cetuximab trials, which reported a DCR of 79.6 and of 76.4%, respectively [
12,
13]. Additionally, compared to the conventional TPEx study, a higher amount of patients were not assessable for response due to early death (26 vs. 11%) in our analysis. We are aware that making assumptions for the definitive reasons for this discrepancy is speculative and no final conclusions can be drawn given the retrospective nature of this analysis. However, we have to point out that a higher fraction of our patients received salvage treatment for recurrence (34%) and/or upfront multimodality treatment such as surgery plus radiotherapy or chemoradiation (44%), thus representing a patient population at increased risk for rapid disease progression.
Modified biweekly TPEx was very well tolerated and no new safety issues arose. Although the majority of patients suffered from a grade 3/4 adverse event, the side effects were well manageable. As compared to the conventional TPEx study, we observed lower rates of severe neutropenia (13%), which is in line with other trials employing a biweekly platinum/taxane protocol [
14].
However, the main advantage of biweekly TPEx should be considered both under quality of life and health economic aspects: Minimizing the number of outpatient visits will reduce health care costs and the need for health care staff and is more convenient for the patient than weekly infusions. From the pharmacological point of view, several trials have shown that biweekly schedules are feasible and might be equivalent to weekly or three weekly regimens in the palliative setting: For cetuximab, it was shown that there is no difference between biweekly and weekly cetuximab in target regulation, pharmacokinetics and pharmacodynamic parameters in colorectal cancer and head and neck cancer patients [
15,
16]. Likewise, it has been demonstrated that cisplatin/docetaxel biweekly is as effective as cisplatin/docetaxel triweekly accompanied with fewer side effects in non-small cell lung cancer patients [
14].
In conclusion, modified biweekly TPEx is a feasible and effective regimen for the first-line therapy of R/M SCCHN patients. Non-inferiority trials are warranted in order to establish this regimen as a standard of care treatment protocol for R/M SCCHN.